This study is not yet accepting patients
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Dates
- study startestimated completion
- Principal Investigator
- by Jospeh A Califano, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Lead Scientist at UCSD
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- University of California, San Diego
- Links
- This publication presents phase I data supporting a neoadjuvant immunoradiotherapy approach for HPVOPC (Human Papilloma Virus Oropharynx Cancer), demonstrating 90% pathologic complete response.
- ID
- NCT05787639
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 29 study participants
- Last Updated